Top buyers by activity, Q1-Q3 2012

The company: Valeant Pharmaceuticals ($VRX)
# deals: 6
Total: $3.3 billion
Acquired: Medicis Pharmaceutical; OraPharma; Natur Produkt; Eyetech Inc.; Probiotica, Pedinol Pharmacal

The company: Amgen ($AMGN)
# deals: 3
Total: $2.17B
Acquired: KAI Pharmaceuticals; Mustafa Nevzat Pharmaceuticals; Micromet   

The company: Bristol-Myers Squibb ($BMY)
# deals: 2
Total: $7.8B
Acquired: Amylin, Inhibitex

Company: GlaxoSmithKline ($GSK)
# deals: 2
Total: $3.7B
Acquired: Human Genome Sciences; Cellzome

Company: Dainippon Pharmaceutical
# deals: 2
Total: $3B
Acquired: Boston Biomedical, Reichhold Chemicals


The company: Perrigo
# deals: 2
Total: $321 million
Acquired: Finetech, Sergeant's Pet Care Products

The company: Takeda
# deals: 2
Total: $267M
Acquired: Multilab; URL Pharma; (added Envoy Therapeutics in October)

The company: Qiagen
# deals: 2
Total: $160M
Acquired: AmniSure International; Ipsogen

The company: Paladin Labs
# deals: 2
Total: $76 million
Acquired: Pharmaplan; Litha Healthcare Group

The company: Opko Health
# of deals: 2
Total: $21M
Acquired: Finetech


Top buyers by activity, Q1-Q3 2012

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.